<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04761627</url>
  </required_header>
  <id_info>
    <org_study_id>20200417</org_study_id>
    <secondary_id>2020-005205-42</secondary_id>
    <nct_id>NCT04761627</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Multicenter, Randomized, Double-blinded Study Evaluating the Pharmacokinetics, Efficacy and Safety of Multiple Switches Between Ustekinumab and ABP 654 Compared With Continued Use of Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate pharmacokinetic similarity, efficacy, safety and&#xD;
      immunogenicity of multiple switches between ustekinumab and ABP 654 compared with continued&#xD;
      use of ustekinumab in participants with moderate to severe plaque psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center study and will enroll approximately 480 participants.&#xD;
&#xD;
      After eligibility confirmation, all participants will be randomized in a 1:1 ratio into 2&#xD;
      treatment arms: continued use of ustekinumab or multiple switches between ustekinumab and ABP&#xD;
      654 at Week 28. The randomization will be stratified by prior biologic use for psoriasis (yes&#xD;
      versus [vs] no) at baseline (Week 0), geographic region, and baseline (Week 0) body weight.&#xD;
&#xD;
      All participants will receive an initial 3 doses of ustekinumab on Day 1 (Week 0), Week 4 and&#xD;
      Week 16. At Week 28, participants will be randomized to continue on ustekinumab or switching&#xD;
      between ABP 654 and ustekinumab every 12 weeks.&#xD;
&#xD;
      At Week 28, efficacy assessments will be conducted including evaluation of Psoriasis and Area&#xD;
      Severity Index (PASI). Participants who do not achieve PASI 50 response or better improvement&#xD;
      at Week 28 will be considered as run-in failures and will not be randomized at Week 28; these&#xD;
      participants will complete End of Study procedures at Week 28. The run-in period will occur&#xD;
      from Day 1 until randomization at Week 28. Those unable to complete the Week 28 visit or did&#xD;
      not have a PASI assessment completed at Week 28 will be discontinued from the study.&#xD;
&#xD;
      The total duration of study participation for each participant will be 68 weeks, with up to 4&#xD;
      weeks for screening and 64 weeks after the first investigational product administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Anticipated">March 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The investigators, study personnel (with the exception of the Data Monitoring Committee (DMC), and unblinded Parexel staff supporting DMC activities and randomization list activities) and the study participants will remain blinded to treatment allocation. ABP 654 and ustekinumab will be coded and labeled in a manner that protects blinding.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve from Time 0 over the Dosing Interval (AUCtau)</measure>
    <time_frame>Week 52 (pre-dose and post-dose) until Week 64</time_frame>
    <description>To evaluate AUCtau in participants with multiple switches between ustekinumab and ABP 654 compared to participants receiving continued use of ustekinumab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax)</measure>
    <time_frame>Week 52 (pre-dose and post-dose) until Week 64</time_frame>
    <description>To evaluate Cmax in participants with multiple switches between ustekinumab and ABP 654 compared to participants receiving continued use of ustekinumab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Concentration (tmax)</measure>
    <time_frame>Week 52 (pre-dose and post-dose) until Week 64</time_frame>
    <description>To assess the tmax in participants with multiple switches between ABP 654 and ustekinumab compared with participants receiving continued use of ustekinumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration at Steady State (Ctrough,ss)</measure>
    <time_frame>Week 28 (pre-dose and post-dose) until Week 52 (pre-dose and post-dose)</time_frame>
    <description>To assess the Ctrough,ss in participants with multiple switches between ABP 654 and ustekinumab compared with participants receiving continued use of ustekinumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Improvement in PASI From Baseline to Week 64</measure>
    <time_frame>Baseline (Day 1) until Week 64</time_frame>
    <description>The PASI is a measure of the average redness (erythema), thickness (induration), and scaliness (scaling); each graded on a 0-4 scale (0 = clear; 1-4= increasing severity) of the lesions, weighted by the area of involvement in the four main body areas (i.e., head, arms, trunk to groin, and legs to top of buttocks). The PASI score ranges from 0 to 72. The higher score represents the worse symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with PASI 75 Response at Week 64</measure>
    <time_frame>Week 64</time_frame>
    <description>Reduction in disease as measured by PASI score. The PASI 75 response is a 75% or greater improvement (reduction in disease [PASI 75]) from baseline in PASI score. The PASI is a measure of the average redness (erythema), thickness (induration), and scaliness (scaling; each graded on a 0-4 scale (0 = clear; 1-4= increasing severity) of the lesions, weighted by the area of involvement in the four main body areas (i.e., head, arms, trunk to groin, and legs to top of buttocks). The PASI score ranges from 0 to 72. The higher score represents the worse symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with PASI 100 Response at Week 64</measure>
    <time_frame>Week 64</time_frame>
    <description>Reduction in disease as measured by PASI score. The PASI 100 response is a 100% improvement (reduction in disease [PASI 100]) from baseline in PASI score. The PASI is a measure of the average redness (erythema), thickness (induration), and scaliness (scaling; each graded on a 0-4 scale (0 = clear; 1-4= increasing severity) of the lesions, weighted by the area of involvement in the four main body areas (i.e., head, arms, trunk to groin, and legs to top of buttocks). The PASI score ranges from 0 to 72. The higher score represents the worse symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events</measure>
    <time_frame>Week 28 until Week 64</time_frame>
    <description>To assess the safety in participants with multiple switches between ABP 654 and ustekinumab compared with participants receiving continued use of ustekinumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Events of Interest</measure>
    <time_frame>Week 28 until Week 64</time_frame>
    <description>To assess the safety in participants with multiple switches between ABP 654 and ustekinumab compared with participants receiving continued use of ustekinumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Anti-drug Antibodies to ABP 654</measure>
    <time_frame>Week 28 until Week 64 (Pre-dose)</time_frame>
    <description>To assess the immunogenicity in participants with multiple switches between ABP 654 and ustekinumab compared with participants receiving continued use of ustekinumab.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Continued-use Group (Ustekinumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive subcutaneous injection of ustekinumab up to Week 52.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Switching Group (Ustekinumab - ABP 654)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will initially receive injection of ustekinumab up to Week 16. Thereafter, starting from Week 28, participants will switch between ABP 654 and ustekinumab every 12 weeks up to Week 52.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>Participants will receive subcutaneous (SC) injection of ustekinumab.</description>
    <arm_group_label>Continued-use Group (Ustekinumab)</arm_group_label>
    <arm_group_label>Switching Group (Ustekinumab - ABP 654)</arm_group_label>
    <other_name>Stelara®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABP 654</intervention_name>
    <description>Participants will receive SC injection of ABP 654.</description>
    <arm_group_label>Switching Group (Ustekinumab - ABP 654)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant has stable moderate to severe plaque psoriasis for at least 6 months&#xD;
&#xD;
          -  Participant has a score of PASI ≥ 12, involvement of ≥ 10% body surface area and&#xD;
             static Physician Global Assessment ≥ 3 at screening and at baseline&#xD;
&#xD;
          -  Participant is a candidate for phototherapy or systemic therapy&#xD;
&#xD;
          -  Participant has previous failure, inadequate response, intolerance, or&#xD;
             contraindication to at least 1 conventional antipsoriatic systemic therapy&#xD;
&#xD;
          -  Female participant should have a negative serum pregnancy test during screening and a&#xD;
             negative urine pregnancy test at baseline&#xD;
&#xD;
          -  Participant or legally acceptable representative is capable of giving signed&#xD;
             Institutional Review Board (IRB)/Independent Ethics Committee (IEC) informed consent&#xD;
&#xD;
          -  Participant has no known history of latent or active tuberculosis&#xD;
&#xD;
          -  Participant with a positive purified protein derivative (PPD) test and a history of&#xD;
             Bacillus Calmette-Guérin (BCG) vaccination is allowed with a negative&#xD;
             Quantiferon/T-spot test&#xD;
&#xD;
          -  Participant with a positive PPD test or participant with a positive or indeterminate&#xD;
             Quantiferon/T-spot test is allowed if he/she has all the following:&#xD;
&#xD;
               -  No symptoms per tuberculosis worksheet provided by the sponsor, Amgen Inc.&#xD;
&#xD;
               -  Documented history of adequate prophylaxis initiation prior to receiving&#xD;
                  investigational product in accordance with local recommendations&#xD;
&#xD;
               -  No known exposure to a case of active tuberculosis after most recent prophylaxis&#xD;
&#xD;
               -  No evidence of active tuberculosis on chest radiograph within 3 months prior to&#xD;
                  the first dose of investigational product&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has erythrodermic psoriasis, pustular psoriasis, guttate psoriasis,&#xD;
             medication induced psoriasis, or other skin conditions at the time of screening (eg,&#xD;
             eczema) that would interfere with evaluations of the effect of investigational product&#xD;
             of psoriasis&#xD;
&#xD;
          -  Participant has an active infection or history of infections&#xD;
&#xD;
          -  Participant has uncontrolled, clinically significant systemic disease, such as&#xD;
             uncontrolled diabetes mellitus, cardiovascular disease, renal disease, liver disease,&#xD;
             or hypertension&#xD;
&#xD;
          -  Participant has a mean QT internal or abnormal long QT syndrome corrected using&#xD;
             Fridericia's formula (QTcF) of &gt; 450 msec (for male participant) or &gt; 470 msec (for&#xD;
             female participant) at baseline that, in the opinion of the Investigator, is abnormal&#xD;
             or clinically significant&#xD;
&#xD;
          -  Participant has moderate to severe heart failure (New York Heart Associate class&#xD;
             III/IV)&#xD;
&#xD;
          -  Participant has known hypersensitivity to the investigational product or to any of the&#xD;
             excipients&#xD;
&#xD;
          -  Participant has laboratory abnormalities at screening&#xD;
&#xD;
          -  Participant has had previous treatment with any agent specifically targeting&#xD;
             interleukin (IL)-12 or IL-23 within 1 year prior to enrollment&#xD;
&#xD;
          -  Participant has received biologic treatment for psoriasis within the previous month or&#xD;
             5 drug half-lives (whichever is longer) prior to enrollment&#xD;
&#xD;
          -  Participant has received any investigational agents within the previous month or 5&#xD;
             half-lives (whichever is longer) prior to enrollment&#xD;
&#xD;
          -  Participant has received non-biologic systemic psoriasis therapy within 4 weeks prior&#xD;
             to enrollment&#xD;
&#xD;
          -  Participant has received ultraviolet A phototherapy (with or without psoralen) or&#xD;
             excimer laser within 4 weeks prior to enrollment, or ultraviolet B phototherapy within&#xD;
             2 weeks prior to enrollment&#xD;
&#xD;
          -  Participant has received topical psoriasis treatment within 2 weeks prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Participant has received other investigational procedures within 4 weeks prior to&#xD;
             enrollment and during the course of the study&#xD;
&#xD;
          -  Female participant is pregnant or breastfeeding or planning to become pregnant while&#xD;
             participating in the study and for at least 5 months after the last dose of&#xD;
             investigational product&#xD;
&#xD;
          -  Sexually active participants and their partners who are of childbearing potential and&#xD;
             not agreeing to use adequate protocol defined contraception methods while&#xD;
             participating in the study and for 5 months after the last dose of investigational&#xD;
             product&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zenith Research Inc.</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research, Inc.</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quest Dermatology Research</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324-4669</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern California Dermatology, Inc</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clearlyderm Dermatology</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33428</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Encore Research Group-Jacksonville Center for Clinical Resea</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Altus Research, Inc.</name>
      <address>
        <city>Palm Springs</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Riverchase Dermatology and Cosmetic Surgery</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028-1013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamilton Research, LLC</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research PC</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dundee Dermatology</name>
      <address>
        <city>West Dundee</city>
        <state>Illinois</state>
        <zip>60118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DS Research</name>
      <address>
        <city>Clarksville</city>
        <state>Indiana</state>
        <zip>47129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DS Research</name>
      <address>
        <city>Corydon</city>
        <state>Indiana</state>
        <zip>47112-2174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Integrated Clinical Trial Services Inc.</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansas Medical Clinic, PA</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamzavi Dermatology</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>New Brighton</city>
        <state>Minnesota</state>
        <zip>55112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skin Specialists PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research, LLC.</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of Central New Jersey</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Dermatology Group, PC</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <zip>07044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Buffalo Medical Group, PC</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>OnSite Clinical Solutions, LLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wilmington Dermatology Center</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research, Inc.</name>
      <address>
        <city>Dripping Springs</city>
        <state>Texas</state>
        <zip>78620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research, Inc - Dermatology</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stephen Miller, MD, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies, LTD., LLP</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology of Seattle</name>
      <address>
        <city>Burien</city>
        <state>Washington</state>
        <zip>98168</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Institute</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2J 7E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Enverus Medical Research</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Irina Turchin PC Inc.</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CCA Medical Research</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SimcoDerm Medical and Surgical Dermatology Center</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guelph Dermatology Research</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1L 0B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr Wei Jing Loo Medicine Professional Corporation</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6H 5L5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DermEdge Research Inc.</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5H 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. S. K. Siddha Medicine Professional Corporation - Doctor's Office</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North York Research Inc. - Dermatology</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M2M 4J5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Ottawa Research Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2C 3N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4W 2N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research Inc.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skinsense Medical Research</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 0H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Confido Private Medical Clinic - General Practice/Medicine</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>Tartu</city>
        <state>Tartumaa</state>
        <zip>50106</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Innomedica OÜ</name>
      <address>
        <city>Tallinn</city>
        <zip>10117</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>50417</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Acad.Fridon Todua Medical Center- Research Institute of Clinical Medicine</name>
      <address>
        <city>Tbilisi</city>
        <state>T'bilisi</state>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LTD Aversi Clinic</name>
      <address>
        <city>Tbilisi</city>
        <state>T'bilisi</state>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LTD Israeli-Georgian Medical Research Clinic Helsicore</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>,,KANVENI - Scientific/Research National Center of Dermatology and Venereology LLC</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>,,Tbilisi Cancer center&quot;LTD</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Derma-Study-Center-FN</name>
      <address>
        <city>Friedrichshafen</city>
        <state>Baden-Württemberg</state>
        <zip>88045</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Licca Clinical Research Institute</name>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatologische Gemeinschaftspraxis Dres.Scholz Sebastian Schilling</name>
      <address>
        <city>Mahlow</city>
        <state>Brandenburg</state>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt am Main - Klinik für Dermatol</name>
      <address>
        <city>Frankfurt/Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fachklinik Bad Bentheim</name>
      <address>
        <city>Bad Bentheim</city>
        <state>Niedersachsen</state>
        <zip>48455</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Hoffmann</name>
      <address>
        <city>Witten</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58453</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Dresden GmbH</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01069</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UK-SH - Lübeck</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Charite Mitte (CCM) - Dermatologie &amp; Allergologie - Dermatologie &amp; Allergologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rothhaar Studien GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10783</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Központ Nagyerdei Campus</name>
      <address>
        <city>Debrecen</city>
        <state>Hajdú-Bihar</state>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brgyógyászati és Allergológiai Magánrendelés</name>
      <address>
        <city>Szolnok</city>
        <state>Jász-Nagykun-Szolnok</state>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qualiclinic Kft</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UNOMEDICALTRIALS Kft</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Derma-B Kft</name>
      <address>
        <city>Debrecen</city>
        <zip>4026</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Riga 1st hospital, Clinic of Dermatology and STD</name>
      <address>
        <city>Riga</city>
        <state>Rga</state>
        <zip>LV1001</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>J.Kisis LtD</name>
      <address>
        <city>Riga</city>
        <state>Rga</state>
        <zip>LV1003</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Smite Aija doctor practice in dermatology, venereology</name>
      <address>
        <city>Talsi</city>
        <zip>LV3201</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne ALL-MED</name>
      <address>
        <city>Krakow</city>
        <state>Maopolskie</state>
        <zip>30-033</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Plejady</name>
      <address>
        <city>Krakow</city>
        <state>Maopolskie</state>
        <zip>30-363</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medycyna Kliniczna</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>00-874</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>RENEW CLINIC Spolka Jawna</name>
      <address>
        <city>Bialystok</city>
        <zip>15-794</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Osrodek Badan Klinicznych</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-065</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne PRATIA Bydgoszcz</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Gdynia</name>
      <address>
        <city>Gdynia</city>
        <zip>81-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krakowskie Centrum Medyczne Sp. z o.o.</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne PROMED</name>
      <address>
        <city>Krakow</city>
        <zip>31-513</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barbara Rewerska Diamond Clinic</name>
      <address>
        <city>Krakow</city>
        <zip>31-559</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia - Centrum Medyczne Nowa Sol</name>
      <address>
        <city>Nowa Sol</city>
        <zip>67-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ETG Siedlce</name>
      <address>
        <city>Siedlce</city>
        <zip>08-110</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>RCMed</name>
      <address>
        <city>Sochaczew</city>
        <zip>96-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia - Szczecinskie Centrum Medyczne</name>
      <address>
        <city>Szczecin</city>
        <zip>71-434</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Evimed</name>
      <address>
        <city>Warszawa</city>
        <zip>02-625</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DermMedica Sp. z o.o.</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-318</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <state>Andalucía</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Estonia</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Biosimilar</keyword>
  <keyword>Psoriasis area and severity index</keyword>
  <keyword>Ustekinumab</keyword>
  <keyword>Skin Diseases</keyword>
  <keyword>Dermatologic Agents</keyword>
  <keyword>Papulosquamous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

